Navigation Links
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
Date:10/30/2008

RICHMOND, Va., Oct. 30 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today reported results for the third quarter and nine-months ended September 30, 2008.

Recent Company Highlights

-- Follow-on Biologics Program

-- Received approval from the United Kingdom's Medicines and

Healthcare products Regulatory Agency to initiate a Phase I clinical

study for the Company's second follow-on biologic

("FOB") product candidate, INS-20. Insmed's INS-20

is a pegylated recombinant form of human G-CSF, and an FOB of the

FDA-approved product Neulasta(R), which had U.S. sales of

approximately $2.4 billion in 2007.

-- IPLEX(TM)

-- Received $3.0 million in cost recovery revenue in the third quarter

related to the expanded access program ("EAP") for

IPLEX(TM). The EAP in Italy to treat patients with Amyotrophic

Lateral Sclerosis ("ALS"), also known as Lou Gehrig's

Disease, currently includes 23 physicians and over 100 subjects have

enrolled;

-- Announced the presentation of clinical study results with Premacure

demonstrating IPLEX(TM) increased serum IGF-I levels into the normal

range in significantly premature infants. Premacure is developing

IPLEX(TM) as a potential treatment for Retinopathy of Prematurity

("ROP") via a Material Transfer Agreement with Insmed.

Based in part on the results of this study, Premacure intends to

initiate a phase II multicenter trial in the ROP indication during

the fourth quarter.

"We continue to execute on our business plan and efficiently advance each of our key clinical programs," said Dr. Geoffrey Allan, President and CEO of Insmed. "Our second FOB ca
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
2. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
3. Insmed to Seek Shareholder Approval for Reverse Split
4. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
5. Insmed to Present at Biosimilars 2008 Conference
6. Insmed to Present at BioPharm Asia 2008 Conference
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. Insmed CEO to Present at Drug Discovery & Development Conference
9. Insmed to Host Second Quarter 2008 Conference Call
10. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
11. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., the first ... hand sanitizer, asks food processors and food handling professionals ... sanitizer they’re currently using to Best Sanitizers’ Alpet® ... critical to fighting cross-contamination and the spread of pathogens ... there are key criteria that make a hand sanitizer ...
(Date:8/28/2014)... are important devices in spintronics, an electronic which ... electrons but also on their spin and the ... electric into magnetic signals and vice versa. Recently, ... the Institute of Physics at Johannes Gutenberg University ... Prague, and Japan, has for the first time ...
(Date:8/28/2014)... month, executives from clinical trial marketing firm BBK Worldwide will ... Patient-Centered Clinical Trials 2014 , to be held at the ... 4-5. Patient recruitment experts Bonnie A. Brescia , ... insights on the benefits of employing an effective patient engagement ... to mobile apps – can be used to drive study ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2
... Anesiva,Inc. (Nasdaq: ANSV ) announced today the ... of its common stock at $4.05 per share, ... on December 12, 2007, for,approximately $45 million in ... $50 million if the underwriters,over-allotment option described below ...
... 13 Synosia Therapeutics today,announced the appointment of ... officer, effective immediately., Dr Blanc, who will ... joins from Syngenta, where he created and led ... and an,experienced biotech entrepreneur, Dr. Blanc helped biotech ...
... Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) announced today ... webcast to provide an update on indiplon Thursday,morning, December ... a.m. Eastern,Time (6:00 a.m. Pacific Time)., Participants can ... 785-424-1071 (International) using the conference,ID: NEURO12. The call can ...
Cached Biology Technology:Anesiva Raises $45 Million in Common Stock Offering 2Synosia Therapeutics Announces Appointment of Chief Business Officer 2
(Date:8/31/2014)... Montral, August 31, ... Nature Neuroscience journal by, Sylvain Williams, PhD, and his ... University Institute and McGill University, opens the door towards better ... as well of the role of an essential element of ... In 2009, they developed a unique approach namely, the ...
(Date:8/29/2014)... Until recently, little has been known about what genetic ... team of scientists, one of whom is a University ... showing that genes controlling the development of the brain ... domestication., The study was published Aug. 28 in ... It is online at http://www.sciencemag.org/ ., The domestication ...
(Date:8/29/2014)... the type and number of connections in transcription factor ... robustness in a study published in PLOS Computational ... the assortativity signature contributes to a network,s resilience against ... the out-out assortativity of TFN models has a greater ... three types of assortativity," said Dov A. Pechenick, PhD, ...
Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2
... MADISON Failing to see the forest for ... declining health of Wisconsin,s forest ecosystems. Even areas ... as forests are increasingly fragmented by roads and development, ... fields, housing tracts, and strip malls, say University of ...
... rings are acclaimed in representing natural climate archives. ... growth of these annual rings depend mainly on temperature ... slight seasonal variations, the correlation is not so ... for Geosciences and their colleagues of the Australian National ...
... Versartis, Inc., an emerging company developing novel biologics ... presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) ... (IL-1ra-rPEG) for treatment of type 1 and type 2 ... DC. Versartis, through a unique licensing agreement with Amunix, ...
Cached Biology News:Isolated forest patches lose species, diversity 2Isolated forest patches lose species, diversity 3Australia's climate: Drought and flooding in annual rings of tropical trees 2Versartis presents positive preclinical data on 2 product candidates at ENDO 09 2
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Complete cell culture media with cytokines...
...
BD IMagnet 1 each...
Biology Products: